Inspire joins AzaSite lawsuit; Pharmascience buys Aegera;

 @FiercePharma: Amylin wins TRO in fight over Lilly marketing pact. News | Follow @FiercePharma

> InSite Vision is joining Merck and Pfizer in filing a patent infringement lawsuit against Sandoz, which recently filed an Abbreviated New Drug Application with the FDA seeking to market a generic version of AzaSite (azithromycin 1 percent ophthalmic solution) before expiration of the patents covering the drug and its use. AzaSite is marketed by Inspire Pharmaceuticals in the U.S., now a wholly-owned subsidiary of Merck. Inspire release

> Pharmascience, the largest generic pharmaceutical company in Quebec, has bought Aegera Therapeutics, a Montreal-based clinical-stage biotechnology company focused on developing targeted therapeutics to address unmet major medical needs, primarily in oncology. Pharmascience release

> The FDA has granted Teva Pharmaceutical Industries approval for the company's ANDA to market a generic version of ViiV Healthcare Company's HIV treatment, Combivir tablets (lamivudine and zidovudine). Shipment is expected to commence during Q4. Teva release

> AstraZeneca Pharmaceuticals LP and AstraZeneca UK Limited have filed suit for patent infringement against Intellipharmaceutics in the U.S. District Court for the District of New Jersey relating to Intellipharmaceutics' FDA application for approval of a generic version of Seroquel XR (quetiapine fumarate extended-release) tablets. Intellipharmaceutics release

> Omega Pharma NV, Belgium's biggest supplier of consumer-health products, rose the most in 2.5 years in Brussels trading after De Tijd reported that the company is in informal talks that may lead to a buyout. Item

> The pharmaceutical research contractors Parexel International Corp. and Icon will partner with Pfizer, they said yesterday, becoming the two preferred providers of clinical trial implementation services to the world's biggest drugmaker. Report

> Merck has sold its South African manufacturing business to Nkunzi Investment Holdings, Engineering News reported, without saying where it got the information. Item

Biotech News

@FierceBiotech: J&J lays out blockbuster R&D strategy, plans for 11 new meds. Story| Follow @FierceBiotech

@JohnCFierce: Amylin, the "jilted lover"--gets its TRO against Lilly. US District Judge Sammartino writes one heck of an order. Filing  | Follow @JohnCFierce

> Rigel raises $130M for PhII trial of asthma drug. Story

> German contender chases Pfizer in oral RA drug pursuit. Item 

> ASCO confab gives Alnylam, RNAi a shot to shine. News

And Finally... Scientists from the University of Warwick have discovered why a newly found form of cholesterol seems to be 'ultra-bad,' leading to increased risk of heart disease. The discovery could lead to new treatments to prevent heart disease in Type 2 diabetes patients and the elderly. University of Warwick release

Suggested Articles

An oncologist leader RBC Capital Markets interviewed expressed comfort that Trodelvy will succeed in earlier-line TNBC and in HR-positive disease.

Gilead Sciences is the latest drugmaker to settle Justice Department claims that its charity contributions were actually kickbacks.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.